These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 12815158)

  • 1. Rescuing the traffic-deficient mutants of rat mu-opioid receptors with hydrophobic ligands.
    Chaipatikul V; Erickson-Herbrandson LJ; Loh HH; Law PY
    Mol Pharmacol; 2003 Jul; 64(1):32-41. PubMed ID: 12815158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opioid agonist and antagonist treatment differentially regulates immunoreactive mu-opioid receptors and dynamin-2 in vivo.
    Yoburn BC; Purohit V; Patel K; Zhang Q
    Eur J Pharmacol; 2004 Sep; 498(1-3):87-96. PubMed ID: 15363980
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ligands regulate cell surface level of the human kappa opioid receptor by activation-induced down-regulation and pharmacological chaperone-mediated enhancement: differential effects of nonpeptide and peptide agonists.
    Chen Y; Chen C; Wang Y; Liu-Chen LY
    J Pharmacol Exp Ther; 2006 Nov; 319(2):765-75. PubMed ID: 16882876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opioid-induced regulation of gene expression in PC12 cells stably transfected with mu-opioid receptor.
    Zarnegar P; Persson AI; Ming Y; Terenius L
    Neurosci Lett; 2006 Apr; 396(3):197-201. PubMed ID: 16377088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adenylyl cyclase superactivation induced by long-term treatment with opioid agonist is dependent on receptor localized within lipid rafts and is independent of receptor internalization.
    Zhao H; Loh HH; Law PY
    Mol Pharmacol; 2006 Apr; 69(4):1421-32. PubMed ID: 16415176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction between the mu opioid receptor and filamin A is involved in receptor regulation and trafficking.
    Onoprishvili I; Andria ML; Kramer HK; Ancevska-Taneva N; Hiller JM; Simon EJ
    Mol Pharmacol; 2003 Nov; 64(5):1092-100. PubMed ID: 14573758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short- and long-term regulation of adenylyl cyclase activity by delta-opioid receptor are mediated by Galphai2 in neuroblastoma N2A cells.
    Zhang L; Tetrault J; Wang W; Loh HH; Law PY
    Mol Pharmacol; 2006 Jun; 69(6):1810-9. PubMed ID: 16525132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Agonist-specific down regulation of mu-opioid receptors: Different cellular pathways are activated by different opioid agonists.
    Binyaminy B; Gafni M; Shapira M; Sarne Y
    Life Sci; 2008 Apr; 82(15-16):831-9. PubMed ID: 18358497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. mu-Opioid receptor internalization: opiate drugs have differential effects on a conserved endocytic mechanism in vitro and in the mammalian brain.
    Keith DE; Anton B; Murray SR; Zaki PA; Chu PC; Lissin DV; Monteillet-Agius G; Stewart PL; Evans CJ; von Zastrow M
    Mol Pharmacol; 1998 Mar; 53(3):377-84. PubMed ID: 9495801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of serine 356 and serine 363 as the amino acids involved in etorphine-induced down-regulation of the mu-opioid receptor.
    Burd AL; El-Kouhen R; Erickson LJ; Loh HH; Law PY
    J Biol Chem; 1998 Dec; 273(51):34488-95. PubMed ID: 9852117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antagonist efficacy in MORS196L mutant is affected by the interaction between transmembrane domains of the opioid receptor.
    Claude-Geppert PA; Liu J; Solberg J; Erickson-Herbrandson LJ; Loh HH; Law PY
    J Pharmacol Exp Ther; 2005 Apr; 313(1):216-26. PubMed ID: 15579496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endogenous regulator of G protein signaling proteins suppress Galphao-dependent, mu-opioid agonist-mediated adenylyl cyclase supersensitization.
    Clark MJ; Neubig RR; Traynor JR
    J Pharmacol Exp Ther; 2004 Jul; 310(1):215-22. PubMed ID: 15014136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of chronic treatment of ohmefentanyl stereoisomers on cyclic AMP formation in Sf9 insect cells expressing human mu-opioid receptors.
    Liu ZH; He Y; Jin WQ; Chen XJ; Shen QX; Chi ZQ
    Life Sci; 2004 Apr; 74(24):3001-8. PubMed ID: 15051423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional significance of the BBXXB motif reversed present in the cytoplasmic domains of the human follicle-stimulating hormone receptor.
    Timossi C; Ortiz-Elizondo C; Pineda DB; Dias JA; Conn PM; Ulloa-Aguirre A
    Mol Cell Endocrinol; 2004 Aug; 223(1-2):17-26. PubMed ID: 15279907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endogenous regulator of g protein signaling proteins reduce {mu}-opioid receptor desensitization and down-regulation and adenylyl cyclase tolerance in C6 cells.
    Clark MJ; Traynor JR
    J Pharmacol Exp Ther; 2005 Feb; 312(2):809-15. PubMed ID: 15383633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opioid mu receptor activation inhibits sodium currents in prefrontal cortical neurons via a protein kinase A- and C-dependent mechanism.
    Witkowski G; Szulczyk P
    Brain Res; 2006 Jun; 1094(1):92-106. PubMed ID: 16733049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the relative efficacy and potency of mu-opioid agonists to activate Galpha(i/o) proteins containing a pertussis toxin-insensitive mutation.
    Clark MJ; Furman CA; Gilson TD; Traynor JR
    J Pharmacol Exp Ther; 2006 May; 317(2):858-64. PubMed ID: 16436499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. mu-Opioid receptor internalization-dependent and -independent mechanisms of the development of tolerance to mu-opioid receptor agonists: Comparison between etorphine and morphine.
    Narita M; Suzuki M; Narita M; Niikura K; Nakamura A; Miyatake M; Yajima Y; Suzuki T
    Neuroscience; 2006; 138(2):609-19. PubMed ID: 16417975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Etorphine increases the number of mu-opioid receptor-positive cells in the cerebral cortex.
    Melone M; Brecha NC; Sternini C; Evans C; Conti F
    Neuroscience; 2000; 100(3):439-43. PubMed ID: 11098106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphatidylinositol-3 kinase is distinctively required for mu-, but not kappa-opioid receptor-induced activation of c-Jun N-terminal kinase.
    Kam AY; Chan AS; Wong YH
    J Neurochem; 2004 Apr; 89(2):391-402. PubMed ID: 15056283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.